PFW Advisors LLC Invests $1.35 Million in Stryker Co. (NYSE:SYK)

PFW Advisors LLC bought a new position in Stryker Co. (NYSE:SYK) during the 4th quarter, Holdings Channel reports. The fund bought 3,750 shares of the medical technology company’s stock, valued at approximately $1,350,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Dunhill Financial LLC increased its stake in Stryker by 94.9% during the third quarter. Dunhill Financial LLC now owns 76 shares of the medical technology company’s stock valued at $27,000 after acquiring an additional 37 shares during the period. Centennial Bank AR increased its position in shares of Stryker by 106.7% during the second quarter. Centennial Bank AR now owns 93 shares of the medical technology company’s stock valued at $32,000 after purchasing an additional 48 shares during the period. Darwin Wealth Management LLC acquired a new position in shares of Stryker in the third quarter valued at $36,000. Hara Capital LLC bought a new position in Stryker in the third quarter worth $42,000. Finally, HBW Advisory Services LLC acquired a new stake in Stryker during the third quarter worth $42,000. Institutional investors and hedge funds own 77.09% of the company’s stock.

Insider Buying and Selling

In other news, CEO Kevin Lobo sold 57,313 shares of Stryker stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $368.70, for a total transaction of $21,131,303.10. Following the transaction, the chief executive officer now owns 100,027 shares in the company, valued at $36,879,954.90. The trade was a 36.43 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 5.90% of the stock is owned by insiders.

Stryker Trading Down 1.3 %

Shares of SYK traded down $4.70 on Monday, reaching $360.96. 1,400,728 shares of the company’s stock were exchanged, compared to its average volume of 1,302,026. Stryker Co. has a 12 month low of $307.23 and a 12 month high of $398.20. The stock has a market capitalization of $137.60 billion, a P/E ratio of 38.69, a price-to-earnings-growth ratio of 2.82 and a beta of 0.95. The company has a current ratio of 1.91, a quick ratio of 1.22 and a debt-to-equity ratio of 0.66. The business has a 50 day moving average price of $375.40 and a two-hundred day moving average price of $357.95.

Stryker (NYSE:SYK) last posted its quarterly earnings results on Tuesday, October 29th. The medical technology company reported $2.87 earnings per share for the quarter, beating analysts’ consensus estimates of $2.77 by $0.10. The company had revenue of $5.49 billion for the quarter, compared to the consensus estimate of $5.37 billion. Stryker had a return on equity of 23.07% and a net margin of 16.34%. The firm’s quarterly revenue was up 11.9% on a year-over-year basis. During the same quarter in the prior year, the business posted $2.46 EPS. Research analysts anticipate that Stryker Co. will post 12.06 earnings per share for the current year.

Stryker Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Tuesday, December 31st will be given a $0.84 dividend. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.93%. This is an increase from Stryker’s previous quarterly dividend of $0.80. The ex-dividend date is Tuesday, December 31st. Stryker’s dividend payout ratio (DPR) is currently 36.01%.

Wall Street Analyst Weigh In

SYK has been the topic of several recent research reports. Evercore ISI lifted their target price on shares of Stryker from $380.00 to $384.00 and gave the company an “outperform” rating in a research report on Wednesday, October 30th. Wells Fargo & Company upped their price objective on Stryker from $405.00 to $427.00 and gave the company an “overweight” rating in a research note on Wednesday, December 11th. Royal Bank of Canada restated an “outperform” rating and set a $425.00 target price on shares of Stryker in a research report on Tuesday, January 7th. Citigroup lifted their price objective on Stryker from $411.00 to $450.00 and gave the company a “buy” rating in a report on Wednesday, December 11th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $442.00 target price on shares of Stryker in a report on Tuesday, January 7th. Four research analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $405.80.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.